FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C
rawpixel / Pixabay

FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C

According to a story from ir.stockpr.com, the biotechnology company CTD Holdings, Inc., recently announced that the US Food and Drug Administration (FDA) has issued an approval for an individual Investigational…

Continue Reading FDA Approves a Program for Expanded Treatment Access in Niemann-Pick Disease Type C

Results from Phase II/III Trial Bring Hope for FDA Approval for New Niemann-Pick Disease Type C Treatment

Niemann-Pick Disease is a genetic lysosomal storage disease. Lipids accumulate in the lysosomes of cells, causing debilitating symptoms. There are three forms of the disease- A, B, and C. Each…

Continue Reading Results from Phase II/III Trial Bring Hope for FDA Approval for New Niemann-Pick Disease Type C Treatment